Loading...

Knight Therapeutics Inc.

GUD.TOTSX
Healthcare
Drug Manufacturers - Specialty & Generic
CA$5.75
CA$0.00(0.00%)

Knight Therapeutics Inc. GUD.TO Peers

See (GUD.TO) competitors and their performances in Stock Market.

Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
GUD.TOCA$5.75+0.00%572.9M57.50CA$0.10N/A
CURA.CNCA$5.22+9.21%4.1B-6.07-CA$0.86N/A
BHC.TOCA$8.83+1.03%3.3B-55.19-CA$0.16N/A
VRNO.CNCA$6.32+6.76%2.2B-5.40-CA$1.17N/A
GTII.CNCA$7.19-0.96%1.7B24.79CA$0.29N/A
CRON.TOCA$2.60-0.38%1B13.68CA$0.19N/A
TRUL.CNCA$4.81-2.63%911.7M-4.50-CA$1.07N/A
CURA.TOCA$1.10-4.35%833.4M-2.47-CA$0.45N/A
TER.CNCA$2.38-0.42%804.8M-1.33-CA$1.79N/A
DHT-UN.TOCA$13.40+0.15%748.6M335.00CA$0.04+3.76%
Showing 1 to 10 of 100 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

GUD.TO vs CURA.CN Comparison

GUD.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GUD.TO stands at 572.9M. In comparison, CURA.CN has a market cap of 4.1B. Regarding current trading prices, GUD.TO is priced at CA$5.75, while CURA.CN trades at CA$5.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GUD.TO currently has a P/E ratio of 57.50, whereas CURA.CN's P/E ratio is -6.07. In terms of profitability, GUD.TO's ROE is +0.01%, compared to CURA.CN's ROE of -0.25%. Regarding short-term risk, GUD.TO is less volatile compared to CURA.CN. This indicates potentially lower risk in terms of short-term price fluctuations for GUD.TO.

Stock Price Comparison

Loading...

Frequently Asked Questions

;